We previously found that HDAC inhibitors can reprogram differentiated triple-negative breast cancer cells to become “induced” tumorigenic, chemoresistant stem-like cells [17] (HDACi-CSCs, Figure 1A). Here, HDAC9 is linked to triple-negative breast carcinoma.